www.sciencedaily.com
Scientists have found that the amino acid arginine effectively combats Alzheimer’s disease (AD) pathology in model organisms. Arginine was shown to inhibit the aggregation of toxic amyloid-beta (Aβ) plaques, a hallmark of AD, and mitigate its harmful effects. Administering arginine orally to flies and mice resulted in reduced plaque formation, decreased inflammation in the brain, and improved cognitive function. Given arginine’s established safety and affordability, researchers suggest it could be a viable option for repurposing as an AD treatment, paving the way for potentially more accessible and cost-effective therapeutic strategies.
